Found: 34
Select item for more details and to access through your institution.
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 5, p. 897, doi. 10.1111/bjh.18643
- By:
- Publication type:
- Article
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 730, doi. 10.1111/bjh.17385
- By:
- Publication type:
- Article
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 356, doi. 10.1111/bjh.16088
- By:
- Publication type:
- Article
Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 4, p. 799, doi. 10.1111/bjh.15634
- By:
- Publication type:
- Article
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 6, p. 1011, doi. 10.1111/bjh.15200
- By:
- Publication type:
- Article
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 2, p. 242, doi. 10.1111/bjh.15560
- By:
- Publication type:
- Article
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 1, p. 77, doi. 10.1111/bjh.15148
- By:
- Publication type:
- Article
<italic>MYD88</italic> mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 578, doi. 10.1111/bjh.14386
- By:
- Publication type:
- Article
<italic>MYD88</italic> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 374, doi. 10.1111/bjh.15049
- By:
- Publication type:
- Article
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 5, p. 717, doi. 10.1111/bjh.14743
- By:
- Publication type:
- Article
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 5, p. 822, doi. 10.1111/bjh.13996
- By:
- Publication type:
- Article
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 4, p. 623, doi. 10.1111/bjh.14279
- By:
- Publication type:
- Article
Rituximab intolerance in patients with Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 4, p. 645, doi. 10.1111/bjh.13794
- By:
- Publication type:
- Article
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 1, p. 81, doi. 10.1111/bjh.13264
- By:
- Publication type:
- Article
Cell‐free DNA analysis for detection of MYD88<sup>L265P</sup> and CXCR4<sup>S338X</sup> mutations in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E250, doi. 10.1002/ajh.26184
- By:
- Publication type:
- Article
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S29, doi. 10.1016/S2152-2650(21)02119-4
- By:
- Publication type:
- Article
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e316, doi. 10.1016/j.clml.2019.09.520
- By:
- Publication type:
- Article
MYD88 and CXCR4 Mutation Rates by Allele-Specific PCR Compared with Diagnostic Next Generation Sequencing Panels in Patients with Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e317, doi. 10.1016/j.clml.2019.09.521
- By:
- Publication type:
- Article
The BCR component SYK is activated by mutated MYD88 and the combined inhibition of SYK and BTK produces synthetic lethality in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.556
- By:
- Publication type:
- Article
Mutated MYD88 regulates transcription of the pro-survival kinase HCK in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.557
- By:
- Publication type:
- Article
Distribution of circulating tumor cells in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e337, doi. 10.1016/j.clml.2019.09.554
- By:
- Publication type:
- Article
Cell-Free DNA as Alternative to Bone Marrow CD19+ Selection for Diagnostic MYD88 L265P in Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e311, doi. 10.1016/j.clml.2019.09.511
- By:
- Publication type:
- Article
Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.060
- By:
- Publication type:
- Article
Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenström's Macroglobulinemia by Next Generation RNA Sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.059
- By:
- Publication type:
- Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-020-0277-6
- By:
- Publication type:
- Article
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. E95, doi. 10.1002/ajh.25730
- By:
- Publication type:
- Article
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 372, doi. 10.1002/ajh.25712
- By:
- Publication type:
- Article
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 4, p. 511, doi. 10.1002/ajh.25023
- By:
- Publication type:
- Article
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 3, p. E69, doi. 10.1002/ajh.24997
- By:
- Publication type:
- Article
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 10, p. 1032, doi. 10.1002/ajh.24477
- By:
- Publication type:
- Article
Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. E312, doi. 10.1002/ajh.24366
- By:
- Publication type:
- Article
Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 8, p. 696, doi. 10.1002/ajh.24052
- By:
- Publication type:
- Article
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 927, doi. 10.1002/jha2.493
- By:
- Publication type:
- Article